David Sankaran has become chief financial officer and senior vice president of Accelrys, replacing John Hanlon, the San Diego-based company said today. Hanlon will leave Accelrys at the end of the month. Sankaran joins the company from Ocular Sciences, a contact lens manufacturer, where he was vice president and corporate controller. Prior to that, he was vice president of investor relations at PeopleSoft, and before that, vice president and corporate controller for Affymetrix. Sankaran holds an MBA from St. Mary's College and a BSc in business from the University of Southern California.
Don Morris has joined Lipomics Technologies as chief technology officer and vice president of bioinformatics, the West Sacramento, Calif.-based company said on Monday. Most recently, he was vice president of informatics at Expression Diagnostics. Prior to that, he was senior director of bioinformatics at Incyte Genomics. From 1993 to 1998, he was lead scientist, and later senior scientist, at Affymetrix. Morris holds a PhD and a BSc in mathematics from Stanford University.
Barry Berkowitz has become president and CEO of Scion Pharmaceuticals, replacing Pravin Chaturvedi, who will remain a consultant, the Medford, Mass.-based company said last week. He joins Scion from Albany Molecular Research, where he was corporate vice president. Berkowitz holds a PhD in pharmacology from the University of California, San Francisco, and a BSc in pharmacy from Northwestern University.
Joseph Donahue, most recently head of global sales and president of Lion Bioscience's US subsidiary, has left the company, according to BioInform, a GenomeWeb newsletter. A company spokeswoman said that a replacement has not yet been named. Donahue joined Lion in 2003 as president of its North American operations. In October 2004, he was appointed co-CEO of the company, along with Thure Etzold. In November, Lion's supervisory board removed Donahue from the executive board and appointed Etzold CEO and Peter Willinger CFO.
K.C. Nicolaouhas been appointed as co-chairman of the scientific advisory board of CeMines, the Golden, Colo.-based company said on Monday. He is a professor and chairman of the department of chemistry at the Scripps Research Institute. Nicolaou is well known for his expertise in synthesizing natural compounds for pharmaceuticals uses, for example the antibiotic vancomycin.
Patricia Goldsmith has become senior vice president of business development, public affairs, and policy at the National Comprehensive Cancer Network, NCCN said yesterday. She used to be vice president for institutional development, public affairs, and marketing at the H. Lee Moffitt Cancer Center and Research Institute in Tampa, Fla., an NCCN member institution.
Philip Watts has been appointed as director of research and development of Bio-Matrix Scientific, the San Diego-based company said yesterday. He joins Bio-Matrix from the California Institute of Technology, where he was conducting research on dynamic fluid engineering as a postdoc. Watts holds a PhD in engineering from Caltech.
Ludwig Terán was named vice president of sales and marketing for SecureSpeed of Chino Hills, Calif. He has previously worked in sales, management and marketing with Amersham, Whatman and Thermo Electron.
John Hulburt was named vice president of finance, chief financial officer, treasurer, and assistant secretary of Datawatch of Lowell, Mass., the company said last week. Hulbert previously was director of audit and SEC compliance at Bruker Biosciences.
Viola Kung has been promoted to partner in the law firm of Howrey Simon Arnold & White of Menlo Park, Calif. Kung previously worked at Molecular Devices and is a research scientist with a PhD from the University of California, Berkeley, and a JD from Santa Clara University School of Law.
Michael Nemzek has joined Velocity11 of Menlo Park, Calif., as vice president of marketing, the company said last week. He previously was general manager of discovery tools at Symyx Technologies. Prior to that, He was an executive with Cellomics; Genosys Biotechnologies, now part of Sigma-Aldrich; Tropix, now part of Applied Biosystems; and EG&G, now part of PerkinElmer. Velocity11 develops automation technologies for pharma/biotech and genomics labs.
Thomas McNallyhas become vice chairman of Whatman, assuming functions from Howard Kelly, who stepped down as CEO in November, the company said last week. McNally, already a non-executive director of Whatman, will retain his new position until a new CEO is appointed. Previously, he held various positions at Abbott Laboratories.
Also, Bob Thian, chairman of Whatman, will be responsible for the integration and management of Schleicher & Schuell, which Whatman acquired in November.
In addition, Hinrich Kehler, until recently chairman of Schleicher & Schuell, has been appointed as a non-executive director. He holds a PhD in physical chemistry.
Tony Hunter, Tony Pawson, and Alexander Levitzki have been jointly awarded the 2005 Wolf Prize in Medicine for their research in cancer development and treatment, the Wolf Foundation said last week. They will equally share the $100,000 prize, which will be presented to them in Jerusalem on May 22.
Hunter, a professor of biology at the Salk Institute, is recognized for discovering tyrosine protein kinases. He holds a PhD from the University of Cambridge, UK.
Pawson, a senior scientist at the Samuel Lunenfeld Research Institute at Mount Sinai Hospital in Toronto and a professor at the University of Toronto, is cited for discovering protein domains essential for mediating protein-protein interactions in cell signaling. He holds a PhD in molecular biology from London University and a BA in biochemistry from Cambridge University.
Levitzki is recognized for developing tyrosine kinase inhibitors to treat cancer, paving the way for drugs such as Gleevec. He is is a professor of biochemistry at the Hebrew University of Jerusalem. Levitzki holds a PhD in biochemistry and biophysics from Hebrew University and the Weizmann Institute of Science.
Erkki Ruoslahtiand Masatoshi Takeichi will receive the 2005 Japan Prize in the category of cell biology for elucidating the molecular mechanisms of cell adhesion, the Science and Technology Foundation of Japan said last week.
The two researchers, who will receive the award in Tokyo on April 20, will share the ¥50 million ($490,000) prize.
Ruoslahti, a professor at the Burnham Institute in La Jolla, Calif., holds and MD, a PhD in immunology, and a BM in medicine from the University of Helsinki in Finland.
Takeichi is the director of the Riken Center for Developmental Biology in Kobe, Japan. He holds a PhD in biophysics from Kyoto University, as well as MSc and BSc degrees in biology from Nagoya University.